Abstract:Aims: Primary hepatic neuroendocrine neoplasms (phNENs) is a rare and poorly understood type of primary liver cancer. We aimed to perform a comprehensive molecular characterization of this malignancy.Methods: Twenty-one cases of phNENs were graded into stepwise increasing malignant potential groups: neuroendocrine tumor grade 1 (NET G1, 3 cases), grade 2 (NET G2, 9 cases), neuroendocrine carcinoma (NEC, 9 cases) based on mitotic activity and proliferative index, according to WHO Classification of Tumors of the Digestive System (2010). The expression of PD-L1(clone 28-8), p53(DO7), NCAM, RB, and synaptophysin were detected. Gene expression profiling, DNA copy number detection, and exome sequencing using formalin-fixed samples from 16 patients with phNENs (9 NETs, 7 NECs) were performed. Comparative genomic analysis was carried out, using independent datasets of pancreas NET (n = 64) and intrahepatic cholangiocarcinoma (ICC) (n = 49).Results: Integrative genomic analysis of phNENs revealed that NEC represents a distinct biliary- derived entity compared with the NET types. NET were, chromosomally stable (mean chromosomal aberrations 4.7 vs. 14.1, p = 0.008), showed significant upregulation of MAPK and PI3K signaling and enrichment of inflammation-related and immune response signatures (p <0.001). NEC tumors were characterized by the mutation signature associated with failure double-strand DNA break repair homologous recombination on its high mutation burdern in samples harbouring BRCA1 or BRCA2 mutation (6/7 vs. 0/9, p <0.001), neural cell adhesion molecule (NCAM) positive (6/7 vs. 1/9, p <0.001), enrichment of progenitor-like signatures, activation of specific oncogenic pathways (i.e., P53-Rb and Wnt), and signatures related to poor clinical outcome. In the NET type, there was a significant correlation in the copy number variation of the ICC, suggesting a clonal origin. Exome sequencing revealed an average of 104 non-synonymous mutations per tumor (2 mean driver mutations per tumor). Among those, TP53 was the most frequently mutated gene (4/7, 57.1%) in phNECs. Intratumor expression of PD-L1 was significantly associated with poorly-differentiated NEC, p53-positive patients. Overall survival rate was significantly correlated to tumor differentiation, growth pattern, necrosis, TP53 mutation (P<0.05), but not correlated to PD-L1expression and vascular invasion(P>0.05).Conclusions: phNEN represents a heterogeneous group of tumors, with the NEC type characterized by features of poor prognosis, and the NET type with common lineage for iCCA. PhNET stands alone as a distinct biliary-derived entity associated with chromosomal stability and active RTK-RAS signaling. The elevated expression of immune related genes and pathways in NENs suggests a therapeutic opportunity for immunotherapy.Note: This abstract was not presented at the meeting.Citation Format: Lingli Chen, Yuan Ji, Jing Zhao, Lingtong Hao, Yixue Li, Xi Zhang, Huichuan Sun, Rongkui Luo, Jing Han, Jie Huang, Yingyong Hou, Jia Liu. Whole-exome sequencing of neuroendocrine neoplasm of the liver reveals recurrent mutations in components of RTK-RAS pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 739.

Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms

Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations

Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor

The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms

Abstract 739: Whole-exome Sequencing of Neuroendocrine Neoplasm of the Liver Reveals Recurrent Mutations in Components of RTK-RAS Pathways

A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors

Targeted Deep Sequencing Reveals the Genetic Heterogeneity in Well-Differentiated Pancreatic Neuroendocrine Tumors with Liver Metastasis.

Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under genomic instability and histological grading

Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours

The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms

Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor

Genomic Dissection of Gastrointestinal and Lung Neuroendocrine Neoplasm.

Oncogenic pathway signatures predict the risk of progression and recurrence in well‐differentiated pancreatic neuroendocrine tumors

Advances on basic and clinical research of liver metastasis of pancreatic neuroendocrine tumors

The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high‐grade transformation

Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Clinical Analysis of Gastroenteropancreatic Neuroendocrine Tumor with Liver Metastasis, Compared with Primary Hepatic Neuroendocrine Tumor.

Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors

Abstract 2253: Comparison of Genomic Alterations in Neuroendocrine Tumors Originated from Different Primary Sites